Candel Therapeutics Stock

candeltx.comHealthcareFunding to Date: $67.6MM

Developer of cancer immunotherapies designed to improve the lives of cancer patients and their families. The company's immunotherapies focus on preventing the recurrence and progression of cancer with low toxicity level which is well suited for the treatment of less aggressive or slower growing cancers such as newly diagnosed prostate cancer, enabling physicians to ensure improved outcomes for their patients and help them recover faster.

Register for Details

For more details on financing and valuation for Candel Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Candel Therapeutics.

Register Today

Team

Management Team

Stephen Rocamboli JD
Chief Business Officer
Laura Aguilar Ph.D
Chief Medical Officer
Estuardo Aguilar-Cordova Ph.D
Chief Executive Officer, Chairman and Co-Founder
Daniel Giroux
Vice President, Manufacturing
Brian Guzik Ph.D
Senior Director, Business Development

Board Members

Christopher Martell
Fred Mermelstein Ph.D
Michael Rubin MD
Northpond Ventures
Udi Meirav Ph.D
Edward Benz Jr.
Estuardo Aguilar-Cordova Ph.D
Glenn Mattes
Paul Manning
Alan Smith
Gregory Gailius
Mitchell Finer Ph.D
Sean Stalfort

Other companies like Candel Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM

News

Advantagene, d.b.a. Candel Therapeutics, a company developing proprietary immuno-oncology platforms, closed a $22.5m Series C financing